Comparative clinical evaluation of @entity4967 plus @entity798 versus @entity3402 plus XXXX in treatment of post-cesarean @entity7288 .

@entity1 @entity801 @entity7288 @entity798 @entity4967 @entity281 @entity3402
A new single-antibiotic combination of @entity4967 and @entity798 was compared with the standard two-drug regimen of @entity3402 and @entity801 in the treatment of post-cesarean @entity7288 . The regimens were as follows: 3 g of @entity4967 plus 100 mg of @entity798 intravenously every four hours; or 600 mg of @entity3402 intravenously every six hours plus 3 to 5 mg/kg per day of @entity801 intramuscularly. The prospective randomized schedule was calculated such that half the @entity1 were assigned to each treatment group. The diagnosis of @entity7288 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity281 . Lochial discharge was foul in most cases. Forty-seven @entity1 were treated. Treatment was successful in all @entity1 who received @entity3402 and @entity801 ; @entity4967 plus @entity798 failed in two of 23 (9 percent) @entity1 . @entity1 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity7288 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity4967 plus @entity798 is effective in the treatment of post-cesarean @entity7288 when compared with the standard regimen of @entity3402 and @entity801 .
